211 related articles for article (PubMed ID: 28780600)
1. The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model.
Frommeyer G; Mittelstedt A; Wolfes J; Ellermann C; Kochhäuser S; Leitz P; Dechering DG; Eckardt L
Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1155-1161. PubMed ID: 28780600
[TBL] [Abstract][Full Text] [Related]
2. Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent.
Frommeyer G; Sterneberg M; Dechering DG; Kaese S; Bögeholz N; Pott C; Fehr M; Bogossian H; Milberg P; Eckardt L
Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 28039911
[TBL] [Abstract][Full Text] [Related]
3. Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug?
Frommeyer G; Sterneberg M; Dechering DG; Ellermann C; Bögeholz N; Kochhäuser S; Pott C; Fehr M; Eckardt L
Int J Cardiol; 2017 Jun; 236():237-243. PubMed ID: 28262346
[TBL] [Abstract][Full Text] [Related]
4. Reduction of atrial fibrillation by Tanshinone IIA in chronic heart failure.
He Z; Sun C; Xu Y; Cheng D
Biomed Pharmacother; 2016 Dec; 84():1760-1767. PubMed ID: 27847200
[TBL] [Abstract][Full Text] [Related]
5. Acute infusion of levosimendan enhances atrial fibrillation in an experimental whole-heart model.
Frommeyer G; Kohnke A; Ellermann C; Dechering DG; Kochhäuser S; Reinke F; Fehr M; Eckardt L
Int J Cardiol; 2017 Jun; 236():423-426. PubMed ID: 28132779
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Frommeyer G; Milberg P; Uphaus T; Kaiser D; Kaese S; Breithardt G; Eckardt L
Cardiovasc Ther; 2013 Dec; 31(6):e63-71. PubMed ID: 23647657
[TBL] [Abstract][Full Text] [Related]
7. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
[TBL] [Abstract][Full Text] [Related]
8. Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure.
Frommeyer G; Schmidt M; Clauß C; Kaese S; Stypmann J; Pott C; Eckardt L; Milberg P
Eur J Heart Fail; 2012 Dec; 14(12):1322-31. PubMed ID: 23099358
[TBL] [Abstract][Full Text] [Related]
9. Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
Frommeyer G; Garthmann J; Ellermann C; Dechering DG; Kochhäuser S; Reinke F; Köbe J; Wasmer K; Eckardt L
Europace; 2018 Aug; 20(8):1375-1381. PubMed ID: 29016765
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine Prevents Levosimendan-Induced Atrial Fibrillation.
Ellermann C; Kohnke A; Dechering DG; Kochhäuser S; Reinke F; Fehr M; Eckardt L; Frommeyer G
Pharmacology; 2018; 102(3-4):138-141. PubMed ID: 29982246
[TBL] [Abstract][Full Text] [Related]
11. Action Potential Triangulation Explains Acute Proarrhythmic Effect of Aliskiren in a Whole-Heart Model of Atrial Fibrillation.
Ellermann C; Mittelstedt A; Wolfes J; Willy K; Leitz P; Reinke F; Eckardt L; Frommeyer G
Cardiovasc Toxicol; 2020 Feb; 20(1):49-57. PubMed ID: 31175534
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine Reduces Digitalis-induced Ventricular Arrhythmias.
Frommeyer G; Weller J; Ellermann C; Bögeholz N; Leitz P; Dechering DG; Kochhäuser S; Wasmer K; Eckardt L
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):526-530. PubMed ID: 28627809
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
Frommeyer G; Ellermann C; Dechering DG; Kochhäuser S; Bögeholz N; Güner F; Leitz P; Pott C; Eckardt L
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1214-1219. PubMed ID: 27283775
[TBL] [Abstract][Full Text] [Related]
14. Comparison of vernakalant and ranolazine in atrial fibrillation.
Frommeyer G; Sterneberg M; Dechering DG; Kochhäuser S; Bögeholz N; Fehr M; Eckardt L
J Cardiovasc Med (Hagerstown); 2017 Sep; 18(9):663-668. PubMed ID: 28692548
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation.
Wolfes J; Ellermann C; Broer N; Rath B; Willy K; Leitz PR; Lange PS; Eckardt L; Frommeyer G
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33092020
[TBL] [Abstract][Full Text] [Related]
16. Atrial Anti-Arrhythmic Effects of Heptanol in Langendorff-Perfused Mouse Hearts.
Tse G; Tse V; Yeo JM; Sun B
PLoS One; 2016; 11(2):e0148858. PubMed ID: 26872148
[TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic properties of ivabradine in an experimental model of Short-QT- Syndrome.
Frommeyer G; Weller J; Ellermann C; Kaese S; Kochhäuser S; Lange PS; Dechering DG; Eckardt L
Clin Exp Pharmacol Physiol; 2017 Sep; 44(9):941-945. PubMed ID: 28556923
[TBL] [Abstract][Full Text] [Related]
18. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
[TBL] [Abstract][Full Text] [Related]
19. New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia.
Frommeyer G; Rajamani S; Grundmann F; Stypmann J; Osada N; Breithardt G; Belardinelli L; Eckardt L; Milberg P
J Card Fail; 2012 Dec; 18(12):939-49. PubMed ID: 23207083
[TBL] [Abstract][Full Text] [Related]
20. Ryanodine-receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an ex vivo model of long-QT syndrome.
Frommeyer G; Krawczyk J; Ellermann C; Bögeholz N; Kochhäuser S; Dechering DG; Fehr M; Eckardt L
J Cardiovasc Electrophysiol; 2018 Mar; 29(3):471-476. PubMed ID: 29314443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
